Fallahi M, Hallaji Z, Tavakolpour S, et al. - In this randomized double‐blind placebo‐controlled trial, researchers tested the effectiveness and safety of topical sirolimus (Rapamycin) 0.2% cream as adjuvant therapy for pulsed dye laser (PDL) for port wine stain (PWS). Fifteen patients with PWS were recruited in this analysis. Each lesion was divided into upper and lower parts, and each part was randomly allocated to receive PDL (4 sessions, 2 months apart) plus sirolimus vs PDL and placebo. The most common adverse effects in the sirolimus group were itching and dryness, contact dermatitis, and none of these were found with placebo. Although the improvement was important subjectively, as an adjuvant to PDL, topical sirolimus 0.2% does not appear to enhance PWS erythema through calorimetric evaluation.